Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.

PREDICT-DNA is a prospective multicenter study of a tumor-informed ultrasensitive ctDNA assay as a biomarker of treatment response in stage II-III HER2-positive or triple-negative breast cancer. A Personalis author affiliation is on the PubMed record.

Journal of Clinical OncologyPubMed 41805422DOI 10.1200/JCO-25-02934